终末期肾病 Medicare 受益人的特征与疫苗接种:2006-2015 年理赔数据分析
该研究分析 2006-2015 年接受 Part B 透析服务的按服务付费 Medicare 终末期肾病受益人的理赔数据,评估流感、乙型肝炎和肺炎球菌疫苗接种覆盖率。流感疫苗接种率从 2006-2007 季的 52% 升至 2015-2016 季的 71%;进入终末期肾病项目后三年内接种乙型肝炎疫苗的概率为 77%,接种任何肺炎球菌疫苗的概率为 53%;45% 的患者完成至少一剂乙型肝炎系列疫苗。
要点
- 流感疫苗接种率从 2006-2007 季的 52% 升至 2015-2016 季的 71%。
- 非白人受益人流感疫苗接种利用率高于白人(p < .001)。
- 进入终末期肾病项目后三年内乙型肝炎疫苗接种概率为 77%,任何肺炎球菌疫苗为 53%。
核心结论
- 地区和机构层面存在改善疫苗接种覆盖率的机会,遵守 ACIP 建议可能直接影响可经疫苗接种减轻的疾病并发症风险。
研究设计与样本
- 分析 2006 年 1 月 1 日至 2015 年 12 月 31 日(流感至 2016 年 6 月 30 日)期间任何时点接受 Part B 透析服务的按服务付费 Medicare 终末期肾病受益人的理赔数据。
- 评估流感疫苗接种率时,限于整个流感季节十二个月连续参加 Medicare Part A 和 B 的受益人。
- 评估透析开始后乙型肝炎和肺炎球菌疫苗覆盖率时,对 2006 至 2015 年间开始透析的所有患者构建 Kaplan-Meier 曲线。
主要发现
- 2006-2015 年每个流感季节平均约 325,000 名终末期肾病透析受益人入组。
- 季节性流感疫苗接种率在 10 年间稳步上升,从 2006-2007 季的 52% 升至 2015-2016 季的 71%。
- 流感疫苗接种增幅最大出现在非白人受益人中,非白人总体利用率高于白人(p < .001)。
- 10 年研究窗口内超过 350,000 名终末期肾病透析受益人开始透析。
- 进入终末期肾病项目后三年内接种乙型肝炎疫苗的概率(77%)高于接种任何肺炎球菌疫苗的概率(53%);45% 的终末期肾病患者在研究期间任何时点完成至少一剂两套乙型肝炎系列(三剂或四剂)中的一剂。
关键数值与推荐
- ACIP 常规推荐终末期肾病透析患者接种三种疫苗:流感疫苗、乙型肝炎疫苗和肺炎球菌疫苗。
- 非白人受益人流感疫苗总体利用率高于白人(p < .001)。
- 进入终末期肾病项目后三年内接种乙型肝炎疫苗概率 77% vs 接种任何肺炎球菌疫苗概率 53%。
- 45% 的终末期肾病患者在研究期间任何时点完成至少一剂两套乙型肝炎系列(三剂或四剂)中的一剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Advisory Committee on Immunization Practices (ACIP) routinely recommends three vaccines - influenza, hepatitis B, and pneumococcal vaccines - for End-Stage Renal Disease (ESRD) dialysis patients. METHODS: We sought to assess vaccination coverage among fee-for-service (FFS) Medicare beneficiaries with ESRD who received Part B dialysis services at any point from January 1, 2006 through December 31, 2015 (through June 30, 2016 for influenza). To assess influenza vaccination rates in a given influenza season, we restricted the population to beneficiaries who were continuously enrolled in Medicare Parts A and B throughout all twelve months of that season. To assess hepatitis B and pneumococcal vaccine coverage following dialysis initiation, we developed a Kaplan-Meier curve for all patients who began dialysis between 2006 and 2015. RESULTS: For influenza vaccination, we identified an average of approximately 325,000 ESRD dialysis beneficiaries enrolled through each influenza season from 2006-2015. Seasonal influenza vaccination rates steadily increased during the 10-year period, from 52% in 2006-2007 to 71% in 2015-2016. The greatest increases in influenza vaccination appear in non-white beneficiaries with overall utilization in non-whites higher than in whites (p < .001). For the hepatitis B and pneumococcal vaccinations, we identified over 350,000 ESRD dialysis beneficiaries who began dialysis over the 10-year study window. The probability of receiving a hepatitis B vaccine within the first three years of entering into the ESRD program was higher (77%) than the probability of receiving any pneumococcal vaccine (53%). 45% of ESRD patients completed at least one dose of the two hepatitis B series (three-dose or four-dose) at any time during the study period. CONCLUSIONS: Opportunities exist at regional and facility levels to improve vaccination coverage. Compliance to ACIP recommendations may directly affect risk for ESRD dialysis patients for complications from diseases that can be mitigated by vaccination.
引用
- Shen AK, Kelman JA, Warnock R, et al. Beneficiary characteristics and vaccinations in the end-stage renal disease Medicare beneficiary population, an analysis of claims data 2006-2015. Vaccine. 2017. PMID: 29132990. doi:10.1016/j.vaccine.2017.10.105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。